19 and older, any sex, with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Longitudinal Changes in Liver Function as Measured by SC SPECT/CT Functional Liver Volume: Cohort A - RadiationPrimary· Baseline, mid-treatment at 2 weeks, and post-treatment at 1 month
Functional liver volume ratio (FLV): represents the percent of the anatomic liver which is functioning and is defined as the ratio of liver functional volume (in cc of volume) to the anatomic liver volume (in cc of volume). Since this outcome measure is a ratio, it is unitless. A higher FLV ratio reflects a higher volume of functional liver.
Baseline FLV Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort A - Radiation
0.36
0.01 – 0.63
Mid-Treatment FLV Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort A - Radiation
0.34
0.00 – 0.67
Post-Treatment FLV Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort A - Radiation
0.25
0.00 – 0.58
Longitudinal Changes in Liver Function as Measured by SC SPECT/CT Liver-to-Spleen Mean: Cohort A - RadiationPrimary· Baseline, mid-treatment at 2 weeks, and post-treatment at 1 month
Liver-to-spleen ratio (L/S mean): represents the magnitude of the global liver function and is defined as the ratio of the mean SC counts in the functional liver to the mean SC counts in the spleen. Since this outcome measure is a ratio, it is unitless. A higher L/S mean ratio reflects higher magnitude of liver function.
Baseline L/S Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort A - Radiation
1.11
0.37 – 2.83
Mid-Treatment L/S Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort A - Radiation
0.96
0.38 – 2.83
Post-Treatment L/S Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort A - Radiation
0.71
0.22 – 2.76
Longitudinal Changes in Liver Function as Measured by SC SPECT/CT Total Liver Function: Cohort A - RadiationPrimary· Baseline, mid-treatment at 2 weeks, and post-treatment at 1 month
Total liver function (TLF): represents the integral liver function and is defined by the product of the functional liver volume (FLV) ratio and liver-to-spleen (L/S) mean ratio. Since this outcome measure is a product of ratios, it is unitless. A higher TLF ratio reflects higher liver function. Median differences were estimated using Wilcoxon (Mann-Whitney) tests.
Baseline TLF Ratio
Group
Value
95% CI
All Patients
0.41
0.00 – 1.78
Child-Pugh A Patients
0.44
0.05 – 1.78
Child-Pugh B/C Patients
0.18
0.00 – 0.55
Mid-Treatment TLF Ratio
Group
Value
95% CI
All Patients
0.29
0.00 – 1.29
Child-Pugh A Patients
0.39
0.11 – 1.29
Child-Pugh B/C Patients
0.15
0.00 – 0.72
Post-Treatment TLF Ratio
Group
Value
95% CI
All Patients
0.18
0.00 – 1.60
Child-Pugh A Patients
0.29
0.03 – 1.60
Child-Pugh B/C Patients
0.09
0.00 – 0.38
Longitudinal Changes in Liver Function as Measured by SC SPECT/CT Spatial Heterogeneity: Cohort A - RadiationPrimary· Baseline, mid-treatment at 2 weeks, and post-treatment at 1 month
To characterize spatial distribution of functional liver, the coefficient of variation (CV) within the FLV will be measured (unitless). A higher CV means more variability or heterogeneity in liver function.
Baseline CV Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort A - Radiation
0.38
0.28 – 0.69
Mid-Treatment CV Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort A - Radiation
0.40
0.29 – 0.89
Post-Treatment CV Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort A - Radiation
0.54
0.35 – 0.84
Longitudinal Changes in Liver Function as Measured by SC SPECT/CT Functional Liver Volume: Cohort B - SurgerySecondary· Baseline, perioperative (2-3 days post surgery), and postoperative (1 month post surgery)
Functional liver volume ratio (FLV): represents the percent of the anatomic liver which is functioning and is defined as the ratio of liver functional volume (in cc of volume) to the anatomic liver volume (in cc of volume). Since this outcome measure is a ratio, it is unitless. A higher FLV ratio reflects a higher volume of functional liver.
Preoperative FLV Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort B - Surgery
0.52
0.39 – 0.58
Perioperative FLV Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort B - Surgery
0.59
0.52 – 0.67
Postoperative FLV Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort B - Surgery
0.54
0.53 – 0.64
Longitudinal Changes in Liver Function as Measured by SC SPECT/CT Liver-to-Spleen Mean: Cohort B - SurgerySecondary· Baseline, perioperative (2-3 days post surgery), and postoperative (1 month post surgery)
Liver-to-spleen ratio (L/S mean): represents the magnitude of the global liver function and is defined as the ratio of the mean SC counts in the functional liver to the mean SC counts in the spleen. Since this outcome measure is a ratio, it is unitless. A higher L/S mean ratio reflects higher magnitude of liver function.
Preoperative L/S Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort B - Surgery
1.53
1.48 – 2.08
Perioperative L/S Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort B - Surgery
1.23
1.10 – 2.78
Postoperative L/S Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort B - Surgery
1.71
0.91 – 2.57
Longitudinal Changes in Liver Function as Measured by SC SPECT/CT Total Liver Function: Cohort B - SurgerySecondary· Baseline, perioperative (2-3 days post surgery), and postoperative (1 month post surgery)
Total liver function (TLF): represents the integral liver function and is defined by the product of the functional liver volume (FLV) ratio and liver-to-spleen (L/S) mean ratio. Since this outcome measure is a product of ratios, it is unitless. A higher TLF ratio reflects higher liver function. Median differences were estimated using Wilcoxon (Mann-Whitney) tests.
Preoperative TLF Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort B - Surgery
0.89
0.57 – 1.09
Perioperative TLF Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort B - Surgery
0.73
0.64 – 1.63
Postoperative TLF Ratio
Group
Value
95% CI
SC SPECT/CT: Cohort B - Surgery
1.1
0.49 – 1.37
Sponsor's own description
This pilot trial studies how well single photon emission computed tomography (SPECT)/computed tomography (CT) with technetium Tc-99m sulfur colloid works in measuring liver function in patients with liver cancer that has or has not spread to other place in the body who are undergoing radiation therapy or surgery. Diagnostic procedures, such as sulfur colloid SPECT/CT scans, may measure normal liver tissue before, during and after treatment and help doctors plan better treatment for liver cancer patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive
· Phase 3
· not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant
· Phase 2
· not yet recruiting
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem
· Phase 1, PHASE2
· recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem
· Phase 2, PHASE3
· not yet recruiting
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
· Phase 2
· recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors
· Phase 3
· recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
· Phase 2
· recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer
· Phase 1
· recruiting
Other University of Washington trials
Trials by the same sponsor.
NCT07430852 — Inherited and Environmental Risks Acting on Body Weight
· NA
· not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc
· Phase 2
· not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn
· NA
· not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 29 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02881554.